The Hetero Ring Has Exactly 13 Ring Carbons (e.g., Erythromycin, Etc.) Patents (Class 514/29)
-
Publication number: 20140200189Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.Type: ApplicationFiled: January 14, 2013Publication date: July 17, 2014Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul-Wahab, Christian D.A. Fozing
-
Publication number: 20140200516Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II; aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: March 18, 2014Publication date: July 17, 2014Applicant: ABBOTT LABORATORIESInventor: Harry A. DUGGER, III
-
Publication number: 20140199413Abstract: The invention relates to formulations for topical use comprising an antiseborrheic agent and an antimicrobial and/or antibacterial agent for the treatment of inflammatory dermatoses. In particular said formulations comprise melatonin and an antimicrobial or antibacterial agent, can be used in the pharmaceutical, cosmetic/cosmeceutical or dermatological field and are particularly suitable for the treatment of acne and of the clinical symptoms associated thereto.Type: ApplicationFiled: January 5, 2012Publication date: July 17, 2014Applicant: NOVAERA S.R.L.Inventor: Giorgio Endrici
-
Publication number: 20140194375Abstract: The invention relates to topical pharmaceutical compositions and methods related to Borrelia burgdorferi toxins, in particular, the present invention provides compositions and methods for the treatment of infections caused by Borrelia burgdorferi and in particular for the prevention of Lyme disease.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicant: Ixodes AGInventors: Gustave HUBER, Huttenes UTA, Caroline ROOSENS-VON BIDDER
-
Publication number: 20140194376Abstract: The present invention provides compounds of formula (I) wherein G1 is oxygen; R1 is hydrogen; R2 is group (P) L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is —C(R4)R4—; R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y2 and Y3 are independently CH or nitrogen, wherein Y2 and Y3 are not both nitrogen; X2 is C—X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl. The invention also provides intermediates useful for the preparation of compounds of formula (I), as well as methods of controlling insects, acarines, nematodes or molluscs using the compounds of formula (I).Type: ApplicationFiled: August 24, 2012Publication date: July 10, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Jerome Yves Cassayre, Peter Renold, Thomas Pitterna, Myriem El Qacemi
-
Publication number: 20140186278Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.Type: ApplicationFiled: September 19, 2013Publication date: July 3, 2014Inventor: Patrick Franke
-
Publication number: 20140170226Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 nm to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.Type: ApplicationFiled: September 26, 2013Publication date: June 19, 2014Applicant: Dermazone Solutions, Inc.Inventor: Michael W. Fountain
-
Publication number: 20140170227Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 nm to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.Type: ApplicationFiled: September 26, 2013Publication date: June 19, 2014Applicant: Dermazone Solutions, Inc.Inventor: Michael W. Fountain
-
Publication number: 20140154317Abstract: An oral pharmaceutical composition for the treatment of helicobacter pylori associated diseases is disclosed comprising a proton pump inhibitor, an antibiotic or a combination of antibiotics, and additionally at least one agent selected from the group consisting of a) taurolidine or taurultam or a combination thereof, b) a zinc amino acid chelate, c) tromethamole, within a fixed-dose combination for oral administration in the form of either an instant release formulation, for example a compressed tablet, granules or the like, or in the form of a biphasic release form, for example a tablet with a slow release core and a compressed outer fast release layer, wherein the tromethamole is always present in instant release formulations.Type: ApplicationFiled: December 3, 2013Publication date: June 5, 2014Inventor: Abo Bakr Mohammed Ali Al-Mehdar
-
Publication number: 20140148402Abstract: Methods for assessing pneumonia in a patient, methods for managing treatment of a patient suspected of having pneumonia, and methods of managing treatment in a patient suffering from pneumonia. The method of assessing pneumonia includes contacting a biological sample with reagents for detection and/or quantification of neutrophil-derived microparticles, determining a level of neutrophil-derived microparticles, and assessing pneumonia if the level is elevated. The method of managing treatment of a patient suspected of having pneumonia includes assessing pneumonia by calculating a concentration of neutrophil-derived microparticles, treating the patient where pneumonia is indicated, and determining treatment response by measuring a post treatment concentration of neutrophil-derived microparticles.Type: ApplicationFiled: November 27, 2013Publication date: May 29, 2014Applicant: University of CincinnatiInventors: Charles C. Caldwell, Kevin R. Kasten, Priya S. Prakash, Bobby L. Johnson, III
-
Publication number: 20140142055Abstract: A method of treating a recurring meibomian gland disorder in a patient includes administering to a patient suffering from recurring meibomian gland disorder a composition comprising a therapeutically effective amount of an azalide antibiotic and a glucocorticoid. The method may thereby reduce the frequency of recurrence of the meibomian gland disorder.Type: ApplicationFiled: June 29, 2012Publication date: May 22, 2014Applicant: INSITE VISION CORPORATIONInventors: Kamran Hosseini, Lyle M. Bowman
-
Publication number: 20140128336Abstract: The present invention concerns products, such as compositions or medical devices, comprising one or more compounds of the Formula I, containing one or more free sulphhydryl groups, where R1 is hydrogen or an acetyl group, and R2 is a sulphhydryl group or a C1-C5 straight chained or branched hydrocarbon chain, optionally containing one or more heteroatoms selected from O, N and S, further containing one or more free sulphhydryl groups, for use in connection with Helicobacter pylori infections or other related infections, either as such or as combinations with antibiotics, whereby the compound(s) and optionally, when present, the antibiotic(s), are mixed with one or more pharmaceutically acceptable carriers providing sustained local release in the stomach or elsewhere in the upper aerodigestive tract.Type: ApplicationFiled: April 18, 2012Publication date: May 8, 2014Applicant: BIOHIT OYJInventors: Matti Härkönen, Tuuli Marvola, Mikko Salaspuro, Osmo Suovaniemi
-
Publication number: 20140128335Abstract: The present invention relates to the use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment of bacteria including those presenting multiple drug resistance (MDR), in particular as efflux pump inhibitors. It also relates to novel polyaminoisoprenyl derivatives, compositions comprising the same, process for preparing the same, and use thereof in antibiotic or antiseptic treatment.Type: ApplicationFiled: February 23, 2012Publication date: May 8, 2014Applicants: UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE DE CORSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean-Michel Bolla, Jean Michel Brunel, Joseph Pierre Felix Casanova, Vannina Lorenzi, Liliane Berti
-
Publication number: 20140120038Abstract: Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against Chlamydia.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicant: Wayne State UniversityInventors: Jayanth Panyam, Judith A. Whittum-Hudson, Alan P. Hudson
-
Publication number: 20140120191Abstract: Disclosed herein are methods and compositions for treating a disorder associated with sequestered bacteria in a mammalian subject comprising the step of administering to the subject a combination therapy comprising streptolysin O and antibiotic therapy in an amount effective to treat the disorder.Type: ApplicationFiled: January 26, 2012Publication date: May 1, 2014Applicant: BEECH TREE LABS INC.Inventor: John McMichael
-
Patent number: 8710019Abstract: The invention relates to topical pharmaceutical compositions and methods related to Borrelia burgdorferi toxins, in particular, the present invention provides compositions and methods for the treatment of infections caused by Borrelia burgdorferi and in particular for the prevention of Lyme disease.Type: GrantFiled: July 24, 2008Date of Patent: April 29, 2014Assignee: Ixodes AGInventors: Gustave Huber, Uta Hüttenes, Caroline Roosens-von Bidder
-
Publication number: 20140107423Abstract: An apparatus for insertion in an ear is provided in one example and includes a drug delivery device for insertion into an external auditory canal, wherein the drug delivery device contains one or more pharmaceutically active agents that can be released from the drug delivery device into the external auditory canal. In more particular instances, the drug delivery device can conform to the profile of the external auditory canal.Type: ApplicationFiled: September 14, 2012Publication date: April 17, 2014Inventor: Yoseph Yaacobi
-
Publication number: 20140100180Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.Type: ApplicationFiled: May 24, 2012Publication date: April 10, 2014Applicant: NOVALIQ GMBHInventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
-
Publication number: 20140094422Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I): wherein R1, R2, etc. are defined as in Claim 1.Type: ApplicationFiled: June 14, 2013Publication date: April 3, 2014Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo
-
Publication number: 20140088031Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.Type: ApplicationFiled: August 21, 2013Publication date: March 27, 2014Applicant: RIB-X PHARMACEUTICALS, INC.Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo, Edward C. Sherer
-
Publication number: 20140080778Abstract: The invention relates to the combination of secnidazole with an antibiotic of the macrolide family, preferably azithromycin 11, for oral treatment of dental infections, which enables a considerable reduction in the length of treatment and the doses administered in comparison with the conventional treatment.Type: ApplicationFiled: May 14, 2012Publication date: March 20, 2014Applicant: MADECAInventor: Pierre-Marie Defrance
-
Publication number: 20140073591Abstract: Multidrug resistance reversers of the d-tetrandrine family are used in conjunction with penicillins and other principle drugs used to treat MRSA.Type: ApplicationFiled: September 12, 2013Publication date: March 13, 2014Applicant: CBA Pharma, Inc.Inventors: Wayne Michael Putnam, Beth D. Gudeman
-
Publication number: 20140038883Abstract: The present invention relates to compounds of formula (I), where R1 and R2, identical or different, are each independently a hydrogen atom or a non-substituted or substituted (C1-C12) alkyl group; R3 is a hydrogen atom or a non-substituted or substituted (C1-C6) alkyl group; R4 is a non-substituted or substituted (C1-C12) alkyl group or an aryl or heteroaryl group, said aryl and heteroaryl groups being non-substituted or substituted; and R5 is a non-substituted or substituted (C1-C12) alkyl group; or R4 and R5 are bonded to one another by a saturated hydrocarbon chain having 3 or 4 carbon atoms, optionally in hydrated form or in the form of a salt that is acceptable for being administered to animals or plants, for the use thereof as a potentiator of the effect of an antimicrobial agent or for the use thereof as an antimicrobial agent.Type: ApplicationFiled: January 27, 2012Publication date: February 6, 2014Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE JOSEPH FOURIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, HOSPICES CIVIL DE LYONInventors: Anne Doleans-Jordheim, Jean Freney, Charles Dumontet, Ahcene Boumend Jel, Jean-Baptiste Veron, Yung-Sing Wong
-
Publication number: 20140031307Abstract: The invention provides novel compounds and compositions and methods for making and using the compounds and compositions.Type: ApplicationFiled: October 10, 2011Publication date: January 30, 2014Applicant: SYNOVO GMBHInventors: Michael W. Burnet, Jan-Hinrich Guse, Christiane Bauerlein, Mary Eggers
-
Publication number: 20140005133Abstract: The invention relates to ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compounds of invention, wherein, T is —C*H(R1)—P-Q; R1 is hydrogen; unsubstituted or substituted lower alkyl, cycloalkyl or aryl; P is heteroaryl ring; Q is unsubstituted or substituted aryl or heteroaryl ring; and P is attached to Q via carbon-carbon link; and R3 is hydrogen or fluorine, With the provision that when R1 is hydrogen, R3 is fluorine.Type: ApplicationFiled: February 3, 2011Publication date: January 2, 2014Inventors: Bharat Trivedi, Prasad Deshpande, Ravikumar Tadiparthi, Sunil Gupta, Santosh Diwakar, Shivaji Pawar, Vijay Patil, Deepak Dekhane, Mahesh Patel, Satish Bhavsar, Amit Mishra, Manish Solanki, Mohammad Jafri, Sachin Bhagwat
-
Publication number: 20130344151Abstract: The invention relates to a novel solid pharmaceutical composition of telithromycin which facilitates swallowing by the patient.Type: ApplicationFiled: August 30, 2013Publication date: December 26, 2013Applicant: AVENTIS PHARMA S.A.Inventor: Christian DESESQUELLE
-
Publication number: 20130303473Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.Type: ApplicationFiled: November 10, 2011Publication date: November 14, 2013Applicant: NOVALIQ GmbHInventor: Clive G. Wilson
-
Publication number: 20130296228Abstract: Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided.Type: ApplicationFiled: April 22, 2013Publication date: November 7, 2013Inventors: Mahesh Vithalbhai PATEL, Sachin Subhash Bhagwat, Mohammad Alam Jafri
-
Publication number: 20130287866Abstract: Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation.Type: ApplicationFiled: October 26, 2011Publication date: October 31, 2013Applicant: ORAL DELIVERY TECHNOLOGY LTD.Inventor: Michael Farber
-
Publication number: 20130281390Abstract: This invention relates to methods of treating dry eye disease. The methods comprise identifying a patient suffering from dry eye disease, and topically administering to the eyes of the patient an effective amount of azithromycin and an effective amount of a retinoid. The method is useful in relieving the signs and symptoms of dry eye disease. This invention also relates to a pharmaceutical composition comprising azithromycin and a retinoid such as retinyl palmitate.Type: ApplicationFiled: December 28, 2011Publication date: October 24, 2013Inventor: Kurt E. Brubaker
-
Publication number: 20130274214Abstract: This invention relates to methods of treating blepharitis. The methods comprise identifying a patient suffering from blepharitis, and topically administering to the eyes of the patient an effective amount of azithromycin and an effective amount of a retinoid. The method is useful in relieving blepharitis signs and symptoms. This invention also relates to a pharmaceutical composition comprising azithromycin and a retinoid such as retinyl palmitate.Type: ApplicationFiled: December 28, 2011Publication date: October 17, 2013Applicant: INSPIRE PHARMACEUTICALS, INC.Inventor: Kurt E. Brubaker
-
Publication number: 20130252915Abstract: New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.Type: ApplicationFiled: May 22, 2013Publication date: September 26, 2013Applicant: Cempra Pharmaceuticals, Inc.Inventor: David E. PEREIRA
-
Publication number: 20130243837Abstract: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an ?2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.Type: ApplicationFiled: April 15, 2013Publication date: September 19, 2013Applicant: Galderma Laboratories Inc.Inventors: Jack DeJovin, Isabelle Jean DeJovin
-
Patent number: 8536143Abstract: Compositions comprising at least one bactericidal antibiotic from the group of macrolides and a non-steroid anti-inflammatory with selective inhibiting activity for cycloxygenase 2 (COX-2). The present invention also refers to a dosage form of said compositions, as well as a method to treat pet animals, particularly dogs and cats. Compositions of the present invention are particularly useful for administration to provide animals with dosages of about 1.0 to 50 mg of compound A/kg of body weight of the animal and about 0.05 to 5.0 mg of compound B/kg of body weight of the animal, being compound A preferably azithromycin and compound B, meloxicam.Type: GrantFiled: March 24, 2008Date of Patent: September 17, 2013Assignee: Ouro Fino Participacoes e Empreendimentos LtdaInventor: Dolivar Coraucci Neto
-
Publication number: 20130237488Abstract: The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.Type: ApplicationFiled: December 20, 2012Publication date: September 12, 2013Applicant: RED HILL BIOPHARMA LTD.Inventors: Thomas Julius Borody, Patrick Gosselin
-
Patent number: 8529935Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: GrantFiled: January 29, 2010Date of Patent: September 10, 2013Assignees: Mero S.R.L., Novagenit S.R.L.Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Publication number: 20130230462Abstract: Disclosed are methods of identifying an individual having a predisposition to the development of a cardiovascular disease, and administering a suitable prophylactic agent to the identified individual to prevent disease. Methods of screening and identifying agents that inhibit bacterial collagen binding protein (CBP)-mediated cell invasion are also disclosed.Type: ApplicationFiled: August 22, 2011Publication date: September 5, 2013Applicants: UNIVERSITY OF FLORIDA, UNIVERSITY OF ROCHESTERInventors: Jacqueline Abranches, José A. Lemos, Robert A. Burne
-
Publication number: 20130231276Abstract: Bacterial multidrug resistance is attenuated in a subject by administering an aminoacyl-tRNA synthetase inhibitor and an antibacterial agent to the subject, wherein the aminoacyl-tRNA synthetase inhibitor is distinct from the antibacterial agent.Type: ApplicationFiled: April 12, 2013Publication date: September 5, 2013Applicant: Brown UniversityInventors: Jason K. Sello, James J. Vecchione
-
Publication number: 20130231298Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit superior antibacterial properties, particularly against Haemophilus influenzae. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.Type: ApplicationFiled: February 22, 2013Publication date: September 5, 2013Applicant: Enanta Pharmaceuticals, Inc.Inventors: Rajesh Iyengar, Yanchun Wang, Ly Tam Phan, Yat Sun Or
-
Publication number: 20130216609Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: March 21, 2013Publication date: August 22, 2013Applicants: The Regents of the University of California, Otonomy, Inc.Inventors: Otonomy, Inc., The Regents of the University of California
-
Publication number: 20130217641Abstract: Pharmaceutical compositions for treating infection from Helicobacter pylori. are described, containing, as the active ingredients, polysorbate and an antibiotic selected from clarithromycin, metronidazole and a mixture thereof. The invention also concerns the use of such compositions as anti-infective agents for the H. pylori eradication treatment, in particular in a combined therapy with a second antibiotic agent and with a gastric proton pump inhibiting agent, or an antacid, or an H2 receptor antagonist, in a therapeutic protocol known as “triple therapy” for the treatment of peptic ulcer.Type: ApplicationFiled: May 26, 2011Publication date: August 22, 2013Applicant: OVER S.R.L.Inventor: Paola Marcolongo
-
Patent number: 8507000Abstract: The present invention is directed to a controlled release formulation in tablet form comprising a pharmaceutically effective amount of an erythromycin derivative and a lubricating effective amount of a lubricant in the absence of material selected from the group consisting of alginic acid or salts thereof or hydrophilic sustained release polymers in amounts effective to retard the release of the erythromycin derivatives in the pharmaceutical composition. It is also directed to a method for facilitating the release of erythromycin derivative from a pharmaceutical composition comprising a therapeutically effective amount of a lubricating effective amount of a lubricant said method comprising adding to said composition an release promoter in tablet disintegrating effective amounts to facilitate the release of the erythromycin derivative from the tablet.Type: GrantFiled: May 6, 2004Date of Patent: August 13, 2013Assignee: Nostrum Pharmaceuticals, Inc.Inventor: Nirmal Mulye
-
Publication number: 20130196939Abstract: A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.Type: ApplicationFiled: January 28, 2013Publication date: August 1, 2013Inventor: Luc MONTAGNIER
-
Publication number: 20130189246Abstract: Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina.Type: ApplicationFiled: November 5, 2010Publication date: July 25, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventor: Konstantin Petrukhin
-
Publication number: 20130183381Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.Type: ApplicationFiled: January 14, 2013Publication date: July 18, 2013Applicant: Celgene CorporationInventor: JEROME B. ZELDIS
-
Publication number: 20130172280Abstract: The invention described herein pertains to a novel macrolide antibacterial agent of formula (I): A-L-Q, as defined herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof. Inter alia, the new macrolide antibacterial agent is active against a number of bacterial species, including resistant species.Type: ApplicationFiled: September 9, 2011Publication date: July 4, 2013Applicant: CEMPRA PHARMACEUTICALS, INC.Inventor: David E. Pereira
-
Publication number: 20130172271Abstract: Methods and formulations for preparing spray dried pharmaceutical products including daptomycin, azithromycin, cyclophosphamide, and voriconazole.Type: ApplicationFiled: January 4, 2013Publication date: July 4, 2013Inventor: Cynthia Fragale
-
Publication number: 20130165368Abstract: A composition for use in the prevention and/or treatment of microbial infection comprising essentially of one or more pure alkanol alkoxylates, diol alkoxylates and/or triol alkoxylates.Type: ApplicationFiled: February 1, 2011Publication date: June 27, 2013Inventors: Ian Steel, Paul Armstrong
-
Patent number: 8470787Abstract: A macrolide derivative, i.e., a hydrate of erythromycin salts, has a molecular formula of C37H67NO13.A.nH2O, n=1.0-11.0, in which A is an organic acid or an organic acids, selected from lactobionic acid, thiocyanic acid, maleic acid, fumaric acid, thiocyanic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, nicotinic acid, lactic acid, citric acid, tartaric acid, aspartic acid, glutamic acid and phosphoric acid. The hydrate has better storage stability and is suitable for the manufacture of a medicament.Type: GrantFiled: July 10, 2009Date of Patent: June 25, 2013Inventor: Li Liu
-
Publication number: 20130150311Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.Type: ApplicationFiled: December 13, 2011Publication date: June 13, 2013Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel